Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Chimeric Antigen Receptor T-Cell Therapy · 1 trial · 23 indications
Will be graded by Common Terminology Criteria for Adverse Events version 4.0. Observed DLT rates will be summarized based on the DLT-Evaluable analysis set. Outcome reported as count of participants in each arm who experienced a DLT.
| Arm | Type | Description |
|---|---|---|
| Treatment (CD20-specific CAR T cell, chemotherapy) | EXPERIMENTAL | Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes. |
| Name | Type | Description |
|---|---|---|
| Chimeric Antigen Receptor T-Cell Therapy | BIOLOGICAL | Given CD20 CAR T cell IV |
| Cyclophosphamide | DRUG | Given IV |
| Laboratory Biomarker Analysis | OTHER | Correlative studies |
| Leukapheresis | PROCEDURE | Undergo leukapheresis |
| Fludarabine Phosphate | DRUG | Given IV |
Inclusion Criteria: * Patients must have B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma. Eligible lymphoma subtypes include (but not limited to): mantle cell, follicular, lymphoplasmacytic, marginal zone, transformed indolent B cell lymphoma (including transf...
Chimeric Antigen Receptor T-Cell Therapy is an investigational cell therapy being studied for the treatment of recurrent B-Cell Non-Hodgkin Lymphoma. It is also being evaluated in clinical trials for other relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
Chimeric Antigen Receptor T-Cell Therapy targets CD20, a protein expressed on the surface of B cells. The therapy uses autologous T cells that are engineered to express a CD20-specific chimeric antigen receptor, enabling the T cells to recognize and attack CD20-positive malignant B cells.
Chimeric Antigen Receptor T-Cell Therapy is being developed by Mustang Bio, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol MBIO. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational cell therapy.
Chimeric Antigen Receptor T-Cell Therapy is in Phase 1 clinical development. It is an investigational therapy that has not been approved by the FDA, and it is currently being studied in an active clinical trial for patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Chimeric Antigen Receptor T-Cell Therapy is being evaluated in clinical trial NCT03277729, a Phase I/II study assessing the safety of autologous T cells engineered to express a CD20-specific chimeric antigen receptor. The trial is active but not recruiting, with an enrollment of 53 participants in the United States.
Chimeric Antigen Receptor T-Cell Therapy is a type of CAR T-cell therapy. It involves engineering a patient's own T cells to express a chimeric antigen receptor that targets CD20, a specific approach within the broader category of CAR T-cell therapies used to treat certain blood cancers.